lung

1234567891011121314151617181920
Across
  1. 1. approves drug indications
  2. 7. number of approved FDA indications for LIBTAYO
  3. 8. objective response rate. Duration of response. Complete response rate. Safety and tolerability.
  4. 11. action taken when a patient experiences a severe adverse reaction
  5. 15. administration method of LIBTAYO
  6. 16. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  7. 18. method to confirm objective response rate (ORR)
  8. 19. color of LIBTAYO
  9. 20. the response restored by LIBTAYO
Down
  1. 2. 360 mg infusion, every 3 weeks
  2. 3. LIBTAYO biologic
  3. 4. immune function inhibited by LIBTAYO
  4. 5. Statistical method often used in evaluating PFS
  5. 6. criteria used to select patients for clinical trials
  6. 9. expresses programmed death receptor
  7. 10. generates fully human therapeutic antibodies, including LIBTAYO
  8. 12. LIBTAYO______ enhances patient access to LIBTAYO
  9. 13. profile in which adverse reactions are reported
  10. 14. first line immune response
  11. 16. organization of clinical trials
  12. 17. tumor staging criteria